Маргарита Леонидовна Тындык

Маргарита Леонидовна Тындык

Auto-generated profile, based on publicly available information

Маргарита Леонидовна Тындык

ФГБУ «НМИЦ онкологии им. Н.Н Петрова» Минздрава России, Санкт-Петербург, Российская Федерация

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in Cell Cycle
Verified
Journal Article
Closed access
VAVladimir N. Anisimov
Vladimir N. Anisimov
LBLev M. Berstein
Lev M. Berstein
PEPeter A. Egormin
Peter A. Egormin
TPTatiana S. Piskunova
Tatiana S. Piskunova
IPIrina G. Popovich
Irina G. Popovich
ASAnna V. Semenchenko
Anna V. Semenchenko
Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors both in aging and in the development of cancer. It is possible that the life-prolonging e...

15 December 2011 in Cell Cycle
Verified
Journal Article
Open access
VAVladimir N. Anisimov
Vladimir N. Anisimov
MZMark A. Zabezhinski
Mark A. Zabezhinski
IPIrina G. Popovich
Irina G. Popovich
TPTatiana S. Piskunova
Tatiana S. Piskunova
ASAnna V. Semenchenko
Anna V. Semenchenko
MBMikhail V Blagosklonny
Mikhail V Blagosklonny
The nutrient-sensing TO R (target of rapamycin) pathway is involved in cellular and organismal aging. Rapamycin, an inhibitor of TO R, extends lifespan in yeast, fruit flies and genetically heterogeneous mice. Here, we demonstrate that lifelong administration of rapamycin extends lifespan in female 129/Sv mice characterized by normal mean lifespan of 2 y. Importantly, rapamycin was administrated intermittently (2 weeks per month) starting from the age of 2 mo. Rapamycin inhibited age-related weight gain, decreased aging rate, increased lifespan (especially in the last survivors) and delayed spontaneous cancer. 22.9% of rapamycin-treated mice survived the age of death of the last mouse in control group. Thus we demonstrated for the first time in normal inbred mice that lifespan can be extended by rapamycin. This opens an avenue to develop optimal doses and schedules of rapamycin as an anti-aging modality.

1 May 2010 in The American Journal of Pathology
Verified
Journal Article
Closed access
PDF file
VAVladimir N. Anisimov
Vladimir N. Anisimov
MZMark A. Zabezhinski
Mark A. Zabezhinski
IPIrina G. Popovich
Irina G. Popovich
TPTatiana S. Piskunova
Tatiana S. Piskunova
ASAnna V. Semenchenko
Anna V. Semenchenko
MBMikhail V. Blagosklonny
Mikhail V. Blagosklonny

1 January 2010 in Cell Cycle
Verified
Journal Article
Closed access
VAVladimir N. Anisimov
Vladimir N. Anisimov
PEPeter A. Egormin
Peter A. Egormin
TPTatiana S. Piskunova
Tatiana S. Piskunova
IPIrina G. Popovich
Irina G. Popovich
MTMargarita L. Tyndyk
Margarita L. Tyndyk
ARAlexey A. Romanyukha
Alexey A. Romanyukha
Population studies have shown that treatment with the antidiabetic biguanide metformin significantly reduced cancer risk. In our animal studies, metformin delayed the onset of mammary adenocarcinom...

1 December 2008 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
VAV. N. Anisimov
V. N. Anisimov
LBL. E. Bakeeva
L. E. Bakeeva
PEP. A. Egormin
P. A. Egormin
OFO. F. Filenko
O. F. Filenko
EIE. F. Isakova
E. F. Isakova
VSV.P. Skulachev
V.P. Skulachev
Very low (nano- and subnanomolar) concentrations of 10-(6′-plastoquinonyl) decyltriphenylphosphonium (SkQ1) were found to prolong lifespan of a fungus ( Podospora anserina), a crustacean (...

20 February 2014 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
IPIrina G Popovich
Irina G Popovich
VAVladimir N Anisimov
Vladimir N Anisimov
MZMark A Zabezhinski
Mark A Zabezhinski
ASAnna V Semenchenko
Anna V Semenchenko
MTMargarita L Tyndyk
Margarita L Tyndyk
MBMikhail V Blagosklonny
Mikhail V Blagosklonny
Target of Rapamycin (TOR) is involved in cellular and organismal aging. Rapamycin extends lifespan and delays cancer in mice. It is important to determine the minimum effective dose and frequency of its administration that still extends lifespan and prevents cancer. Previously we tested 1.5 mg/kg of rapamycin given subcutaneously 6 times per two weeks followed by a two-week break (1.5 × 6/bi-weekly schedule: total of 6 injections during a 4-week period). This intermittent treatment prolonged lifespan and delayed cancer in cancer-prone female FVB/N HER-2/neu mice. Here, the dose was decreased from 1.5 mg/kg to 0.45 mg/kg per injection. This treatment was started at the age of 2 months (group Rap-2), 4 months (Rap-4), and 5 months (Rap-5). Three control groups received the solvent from the same ages. Rapamycin significantly delayed cancer and decreased tumor burden in Rap-2 and Rap-5 groups, increased mean lifespan in Rap-4 and Rap-5 groups, and increased maximal lifespan in Rap-2 and Rap-5 groups. In Rap-4 group, mean lifespan extension was achieved without significant cancer prevention. The complex relationship between life-extension and cancer-prevention depends on both the direct effect of rapamycin on cancer cells and its anti-aging effect on the organism, which in turn prevents cancer indirectly. We conclude that total doses of rapamycin that are an order of magnitude lower than standard total doses can detectably extend life span in cancer-prone mice.